domvanalimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
domvanalimab

GtoPdb Ligand ID: 13983

Synonyms: AB-154 | AB154

Compound class: Antibody

Comment: Domvanalimab (AB154) is an anti-TIGIT monoclonal antibody. It is designed to be 'Fc-silent' as a method to prevent depletiion of regulatory T cells (which would otherwise be promoted by Fc-mediated antibody dependent cellular cytotoxicity). Silencing TIGIT has two functions. It negates the inhibitory action of TIGIT binding to poliovirus receptor (PVR, CD155) which blocks immune suppression, and it leaves PVR available to interact with the costimulatory DNAM-1 (CD226) molecule. The combined effects potentiate a natural killer (NK) cell and T cell-mediated anti-tumour immune response.

Immunopharmacology Comments
Blocks TIGIT/PVR-mediated immune suppression, and leaves PVR available to interact with the costimulatory DNAM-1 (CD226) molecule. This promotes robust anti-tumour immune response by NK and T cells.

Immunopharmacology Comments

Blocks TIGIT/PVR-mediated immune suppression, and leaves PVR available to interact with the costimulatory DNAM-1 (CD226) molecule. This promotes robust anti-tumour immune response by NK and T cells.